ABSTRACT
The pathogenic mechanism of dementia is still unknown, and the fundamental treatment remains to be established. Thus, there is growing interest in preventing dementia through diet. One of the functional ingredients attracting attention is docosahexaenoic acid. We conducted a 12-month, randomized, double-blind, placebo-controlled clinical trial in healthy elderly Japanese individuals with a Mini-Mental State Examination score of 28 or higher at baseline using a docosahexaenoic acid-enriched milk beverage containing 297 mg docosahexaenoic acid and 137 mg eicosapentaenoic acid. Consumption of a docosahexaenoic acid-enriched milk beverage increased the fatty acid levels of docosahexaenoic acid and eicosapentaenoic acid in erythrocyte membranes, which was the primary outcome of this study. Moreover, intake of this beverage prevented age-related cognitive decline and decreased serum bone resorption marker levels. Our data demonstrate that, even at a low dose, long-term daily intake of docosahexaenoic acid prevents dementia and may show beneficial effect on bone health.
Subject(s)
Alkaline Phosphatase/blood , Bone Resorption/diagnosis , Bone Resorption/prevention & control , Cognitive Aging , Cognitive Dysfunction/etiology , Cognitive Dysfunction/prevention & control , Dementia/prevention & control , Dietary Supplements , Docosahexaenoic Acids/administration & dosage , Eating/physiology , Milk , Tartrate-Resistant Acid Phosphatase/blood , Aged , Animals , Asian People , Biomarkers/blood , Dementia/etiology , Docosahexaenoic Acids/blood , Double-Blind Method , Eicosapentaenoic Acid/administration & dosage , Erythrocyte Membrane/metabolism , Female , Humans , Male , Middle AgedABSTRACT
INTRODUCTION: Aromatase inhibitor (AI)-associated bone loss increases the risk of bone fracture and reduces patients' quality of life, making it a critical issue worldwide. We conducted a prospective non-randomized clinical trial (UMIN-CTR, UMIN 000016173) to assess the effect of denosumab on bone loss in patients treated with adjuvant AI and have previously reported the results at 12 and 24 months. This study aimed to present the results at 36 months of treatment with denosumab for osteopenia in breast cancer patients who were undergoing treatment with adjuvant AI; 36 months is the longest denosumab treatment period reported so far. MATERIALS AND METHODS: Patients received 60-mg denosumab subcutaneously every 6 months. Daily supplements containing 500-mg elemental calcium and at least 400 international units of vitamin D were highly recommended throughout the study period. The levels of bone mineral density (BMD) and bone turnover markers, serum tartrate-resistant acid phosphatase isoform 5b, and bone alkaline phosphatase were determined at baseline and 6, 12, 18, 24, and 36 months. RESULTS: At 36 months, the bone mineral density of the lumbar spine, right femoral neck, and left femoral neck were found to increase by 8.8% (95% confidence interval CI 7.6-10.1), 4.3% (95% CI 3.0-5.5), and 3.1% (95% CI 2.1-4.1), respectively. No non-traumatic clinical fractures occurred in patients receiving AI and denosumab. CONCLUSION: Twice-yearly administration of denosumab to the breast cancer patients treated with adjuvant AI, regardless of the skeletal site, resulted in consistent increases in BMD without severe adverse events at 36 months.
Subject(s)
Adjuvants, Pharmaceutic/therapeutic use , Aromatase Inhibitors/therapeutic use , Breast Neoplasms/drug therapy , Denosumab/therapeutic use , Adjuvants, Pharmaceutic/pharmacology , Aged , Aged, 80 and over , Alkaline Phosphatase/blood , Aromatase Inhibitors/pharmacology , Biomarkers/blood , Bone Density/drug effects , Bone Density Conservation Agents/therapeutic use , Bone Remodeling/drug effects , Breast Neoplasms/blood , Denosumab/adverse effects , Denosumab/pharmacology , Female , Fractures, Bone/blood , Fractures, Bone/drug therapy , Humans , Middle Aged , Prospective Studies , Tartrate-Resistant Acid Phosphatase/bloodABSTRACT
We have previously reported that patients with severe motor and intellectual disabilities (SMID) have a high prevalence of vitamin K deficiency both in the liver and bone. Thus, vitamin K therapy for SMID patients should be considered. In the present study, we have studied the efficacy of nutritional therapy with vitamin K1 for improving their vitamin K status and bone metabolism markers in patients with SMID. During the 3-mo period, 19 patients under enteral feeding received vitamin K1 treatment, the dose of which was determined to meet each subject's energy requirement. Biomarkers of vitamin K insufficiency; protein induced by vitamin K absence or antagonist-II (PIVKA-II), undercarboxylated osteocalcin (ucOC), intact osteocalcin (intact OC) and bone turnover markers (tartrate-resistant acid phosphatase-5b: TRACP-5b and bone alkaline phosphatase: BAP) were measured at baseline and post treatment. The ucOC/OC ratio was calculated as a more sensitive index than ucOC for vitamin K status in the bone. After treatment, the median vitamin K intake increased from 66 to 183 µg/d, and serum levels of PIVKA-II and ucOC/OC ratio were significantly decreased. Decrements of serum ucOC level and ucOC/OC ratio were significantly associated with vitamin K intake, indicating that both markers well reflect the dose-dependent vitamin K effects. Serum levels of BAP and TRACP-5b were significantly increased after vitamin K1 therapy. Nutritional therapy with vitamin K1 effectively improved the markers for vitamin K status and bone turnover, and was considered to be a good candidate for treatment in SMID patients.
Subject(s)
Bone Remodeling , Bone and Bones/metabolism , Intellectual Disability/complications , Motor Disorders/complications , Vitamin K 1/therapeutic use , Vitamin K Deficiency/drug therapy , Adult , Alkaline Phosphatase/blood , Biomarkers/blood , Disabled Persons , Female , Humans , Intellectual Disability/blood , Middle Aged , Motor Disorders/blood , Nutrition Therapy , Nutritional Requirements , Nutritional Status , Osteocalcin/blood , Protein Precursors/blood , Prothrombin , Severity of Illness Index , Tartrate-Resistant Acid Phosphatase/blood , Treatment Outcome , Vitamin K 1/blood , Vitamin K Deficiency/blood , Vitamin K Deficiency/etiology , Young AdultABSTRACT
(1) Background: Magnesium supplementation may be effective for the prevention of cardiometabolic diseases, but the mechanisms are unclear. Proteomic approaches can assist in identifying the underlying mechanisms. (2) Methods: We collected repeated blood samples from 52 individuals enrolled in a double-blind trial which randomized participants 1:1 to oral magnesium supplementation (400 mg magnesium/day in the form of magnesium oxide) or a matching placebo for 10 weeks. Plasma levels of 91 proteins were measured at baseline with follow-up samples using the Olink Cardiovascular Disease III proximity extension assay panel and were modeled as arbitrary units in a log2 scale. We evaluated the effect of oral magnesium supplementation for changes in protein levels and the baseline association between serum magnesium and protein levels. The Holm procedure was used to adjust for multiple comparisons. (3) Results: Participants were 73% women, 94% white, and had a mean age of 62. Changes in proteins did not significantly differ between the two intervention groups after correction for multiple comparisons. The most statistically significant effects were on myoglobin [difference -0.319 log2 units, 95% confidence interval (CI) (-0.550, -0.088), p = 0.008], tartrate-resistant acid phosphatase type 5 (-0.187, (-0.328, -0.045), p = 0.011), tumor necrosis factor ligand superfamily member 13B (-0.181, (-0.332, -0.031), p = 0.019), ST2 protein (-0.198, (-0.363, -0.032), p = 0.020), and interleukin-1 receptor type 1 (-0.144, (-0.273, -0.015), p = 0.029). Similarly, none of the associations of baseline serum magnesium with protein levels were significant after correction for multiple comparisons. (4) Conclusions: Although we did not identify statistically significant effects of oral magnesium supplementation in this relatively small study, this study demonstrates the value of proteomic approaches for the investigation of mechanisms underlying the beneficial effects of magnesium supplementation. Clinical Trials Registration: ClinicalTrials.gov NCT02837328.
Subject(s)
Cardiovascular Diseases/prevention & control , Dietary Supplements , Magnesium Oxide/administration & dosage , Proteomics/methods , Administration, Oral , Biomarkers/blood , Blood Proteins , Cardiovascular Diseases/diagnosis , Double-Blind Method , Female , Humans , Interleukin-1 Receptor-Like 1 Protein/blood , Magnesium/blood , Middle Aged , Myoglobin , Tartrate-Resistant Acid Phosphatase/blood , Tumor Necrosis Factor Ligand Superfamily Member 13/bloodABSTRACT
ETHNOPHARMACOLOGICAL RELEVANCE: Abeliophyllum distichum Nakai (AD), called Miseon, is one of Korea's monotypic endemic species. As a folk remedy, the AD has been used to treat inflammatory disease, stomachaches, diarrhea, and gynecologic disease in Korea. Some researchers have reported that the AD has anti-cancer, anti-inflammatory, and anti-oxidant effects. But the protective effect of AD leaf for osteoporosis has not been reported yet. AIM OF THE STUDY: This study aimed to analyze the effects and mechanism of AD-ethyl acetate fraction (EA) extract on the osteoporosis, one of the gynecologic disease. MATERIALS AND METHODS: The RAW 264.7 cells were used as a model for RANKL-induced osteoclastogenesis. We measured the TRAcP activity, expressions of NFATc1, c-fos, and MAPK to investigate the effect of AD-EA. OVX-induced osteoporosis rat model was used as menopausal osteoporosis. After both ovaries were removed through a surgical procedure, and AD-EA or 17b-estradiol was orally administered for 8 weeks. BMD of femurs was measured as well as the bone morphometric parameter, such as BV/TV, trabecular thickness, number and surface using a micro CT. RESULTS: AD-EA significantly inhibited TRAcP activity, actin ring formation, pit formation and the expressions of osteoclast-related genes in a dose-dependent manner through the inhibition of the MAPK and c-fos/NFATc1 pathway. In addition, low dose administration of AD-EA improved the deterioration of trabecular bone microarchitecture caused by OVX through the inhibition of bone resorption by TRAcP and CTK. CONCLUSIONS: These results suggest that AD-EA may contribute to the therapy of osteoporosis caused by menopause in women.
Subject(s)
Osteogenesis/drug effects , Osteoporosis, Postmenopausal/drug therapy , Ovariectomy , Plant Extracts/pharmacology , RANK Ligand/metabolism , RANK Ligand/pharmacology , Animals , Bone Resorption/drug therapy , Bone and Bones/pathology , Carbonic Anhydrase II/metabolism , Cathepsin K/metabolism , Femur , Humans , JNK Mitogen-Activated Protein Kinases/metabolism , Matrix Metalloproteinase 9/metabolism , Mice , Mitogen-Activated Protein Kinase Kinases/metabolism , NFATC Transcription Factors/metabolism , Osteoclasts/drug effects , RAW 264.7 Cells , Rats , Rats, Sprague-Dawley , Receptor Activator of Nuclear Factor-kappa B , Receptors, Cell Surface , Republic of Korea , Signal Transduction/drug effects , TNF Receptor-Associated Factor 6/metabolism , Tartrate-Resistant Acid Phosphatase/blood , Tartrate-Resistant Acid Phosphatase/metabolism , Vacuolar Proton-Translocating ATPases/metabolism , p38 Mitogen-Activated Protein Kinases/metabolismABSTRACT
OBJECTIVES: We assessed the severity and pathology of osteoporosis in children and adults with severe motor and intellectual disabilities (SMID) by evaluating bone enzymes, by which we aimed to determine adequate treatment approaches for preventing fractures. METHODS: Ninety patients (44 men, 46 women; mean age, 34.5â¯years) underwent bone quality assessment. Quantitative ultrasonography (QUS) was used to measure the T-score and Z-score of the calcaneus, and blood tests were used to measure bone-specific alkaline phosphatase and tartrate-resistant acid phosphatase 5b levels as bone formation and resorption markers, as well as calcium, phosphorous, and parathyroid hormone levels as routine examination. RESULTS: Bone formation and resorption marker levels were within normal ranges in adults, although they were high during the growth period in children and adolescents and in elderly women. Patients receiving tube feeding showed a significantly lower Z-score than those without tube feeding. Tube feeding was a significant factor for the Z-score, whereas age, vitamin supplements, and anti-epileptic drugs were not. CONCLUSIONS: The severity of osteoporosis in SMID started during the growth period and seems to be caused by a lack of an effective increase in bone mineral density. Any treatment should be started during the growth period. More study about tube feeding is needed.
Subject(s)
Bone Density , Enteral Nutrition , Intellectual Disability , Mobility Limitation , Motor Disorders , Osteoporosis/diagnosis , Tartrate-Resistant Acid Phosphatase/blood , Adolescent , Adult , Aged , Child , Child, Preschool , Comorbidity , Enteral Nutrition/statistics & numerical data , Female , Humans , Intellectual Disability/epidemiology , Male , Middle Aged , Motor Disorders/epidemiology , Osteoporosis/blood , Osteoporosis/diagnostic imaging , Osteoporosis/epidemiology , Tokyo/epidemiology , Ultrasonography , Young AdultABSTRACT
INTRODUCTION: In terms of the balance between benefits and risks of long-term treatment with bisphosphonate, uncertainties remain regarding the optimal treatment duration. We investigated effects of continuous long-term treatment for 10 years with bisphosphonate in postmenopausal osteoporosis patients. MATERIALS AND METHODS: Fifty five patients in the outpatient clinic of our hospital have been continuously treated with alendronate or risedronate for 10 years. All data were retrospectively collected. The age, height, weight, total muscle volume, total fat volume, and BMD at the lumbar spine, total hip and distal 1/3 radius, alkaline phosphatase (ALP), urinary type I collagen cross-linked N-telopeptide (uNTX) and tartrate-resistant acid phosphatase-5b (TRAP5b), calcium (Ca) and phosphate (P) levels were measured pre- and after the start of 10-year continuous treatment. RESULTS: BMD at the lumbar spine increased continuously over the 10-year period, while BMD at the total hip slightly but significantly decreased, and that at the 1/3 radius did not show any significant change over the 10 years. Serum Ca value was significantly decreased after the start of treatment, and became stable within the reference range from the second year. Bone resorption markers such as uNTX and TRAP5b significantly decreased from the second year after the start of treatment and no significant changes were observed thereafter. There were no serious medical adverse events including atypical femoral fractures and osteonecrosis of the jaw. CONCLUSION: We believe that the continuous use of alendronate and risedronate for 10 years could be an option for the treatment of postmenopausal osteoporosis patients.
Subject(s)
Asian People , Diphosphonates/therapeutic use , Osteoporosis/drug therapy , Aged , Aged, 80 and over , Alendronate/pharmacology , Alendronate/therapeutic use , Alkaline Phosphatase/blood , Bone Density/drug effects , Calcium/blood , Collagen Type I/blood , Diphosphonates/pharmacology , Female , Humans , Japan , Osteoporosis/blood , Osteoporosis/chemically induced , Osteoporosis/physiopathology , Osteoporosis, Postmenopausal/drug therapy , Peptides/blood , Phosphorus/blood , Retrospective Studies , Risedronic Acid/therapeutic use , Tartrate-Resistant Acid Phosphatase/blood , Time Factors , Treatment OutcomeABSTRACT
Previous studies have shown that Tougu Xiaotong capsule (TGXTC) has therapeutic effects on knee osteoarthritis (OA) through multiple targets. However, the mechanisms of action underlying its regulation of subchondral bone reconstruction remain unclear. In this study, we investigated the effects of TGXTC on subchondral bone remodeling. Eighteen six-month-old New Zealand white rabbits of average sex were randomly divided into the normal, model and TGXTC groups. The rabbit knee OA model was induced by a modified Hulth's method in the model and TGXTC groups, but not the normal group. Five weeks postoperatively, intragastric administration of TGXTC was performed for four weeks. After drug administration, the medial femoral condyle and tibia were prepared for observation of cartilage histology via optical microscopy and micro-computed tomography, the serum was collected for biochemical parameters assay and the subchondral bone isolated from the lateral femoral condyle was collected for detection of IL-1ß and TNF-α mRNA and protein by reverse transcription-quantitative polymerase chain reaction and western blot analysis, respectively. The results showed that treatment with TGXTC significantly mitigated cartilage injury and subchondral bone damage, improved the parameter of subchondral trabecular bone, decreased alkaline phosphatase and tartrate-resistant acid phosphatase activity, and significantly reducing the osteoprotegerin/receptor activator of nuclear factor-κB ligand ratio, reduced the expression of IL-1ß and TNF-α mRNA and protein. These results suggest that TGXTC could delay the pathological development of OA by regulating subchondral bone remodeling through regulation of bone formation and bone resorption and its relating inflammatory factors, and this may partly explain its clinical efficacy in the treatment of knee OA.
Subject(s)
Bone Remodeling , Drugs, Chinese Herbal/therapeutic use , Osteoarthritis, Knee/drug therapy , Osteoarthritis, Knee/physiopathology , Alkaline Phosphatase/blood , Animals , Bone Remodeling/drug effects , Cancellous Bone/drug effects , Cancellous Bone/pathology , Cartilage, Articular/drug effects , Cartilage, Articular/pathology , Drugs, Chinese Herbal/pharmacology , Female , Interleukin-1beta/genetics , Interleukin-1beta/metabolism , Osteoarthritis, Knee/diagnostic imaging , Osteoarthritis, Knee/pathology , Osteoprotegerin/blood , RANK Ligand/blood , RNA, Messenger/genetics , RNA, Messenger/metabolism , Rabbits , Tartrate-Resistant Acid Phosphatase/blood , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/metabolism , X-Ray MicrotomographyABSTRACT
BACKGROUND: Bone turnover markers (BTMs) are proposed as alternative indicators for bone mineral density in diagnosis and management of osteoporosis. However, little is known about the effects of vitamin D supplementation on BTMs in nonwhite populations. OBJECTIVE: We aimed to investigate the responses in BTMs after vitamin D supplementation in Asians. METHODS: In this secondary data analysis of a randomized, double-blind, placebo-controlled trial, 448 Chinese adults [mean ± SD age: 31.9 ± 8.0 y; mean ± SD body mass index (kg/m2): 22.1 ± 2.6; 69% were women] with vitamin D deficiency (serum 25-hydroxyvitamin D [25(OH)D] <50 nmol/L) received 2000 IU/d cholecalciferol or placebo for 20 wk. Serum concentrations of 25(OH)D, parathyroid hormone (PTH), calcium, and markers of bone formation and resorption were measured at weeks 0 and 20. Intention-to-treat analysis was applied, and between-group differences were compared by general linear models with adjustments. RESULTS: Cholecalciferol supplementation increased the serum bone alkaline phosphatase (BALP) concentration (+1.7 ± 1.9 µg/L) significantly more than placebo (+1.1 ± 1.7 µg/L; P = 0.004), but not circulating concentrations of procollagen type I N-terminal propeptide (PINP), ß-isomerized C-terminal telopeptide of type I collagen (ß-CTX), or tartrate-resistant acid phosphatase 5b (TRAP5b) (P ≥ 0.53). Notably, a pooled analysis indicated that changes in serum 25(OH)D were positively associated with changes in serum BALP, PINP, and TRAP5b (r = 0.07-0.16, P ≤ 0.02), but inversely with changes in PTH (r = -0.15, P < 0.001). Among cholecalciferol-treated participants, individuals who achieved serum 25(OH)D ≥75 nmol/L had greater increases in serum ß-CTX (224% compared with 146%; P = 0.02) and TRAP5b (22.2% compared with 9.1%; P = 0.007), but smaller decreases in serum calcium (-1.3% compared with -1.9%; P = 0.005) and calcium-phosphorus product (-2.6% compared with -3.3%; P = 0.02) compared with those with serum 25(OH)D <75 nmol/L. CONCLUSIONS: Daily supplementation with 2000 IU cholecalciferol for 20 wk may promote bone formation in Chinese adults with vitamin D deficiency. More studies are needed to elucidate the potential clinical implications of BTMs.This trial was registered at clinicaltrials.gov as NCT01998763.
Subject(s)
Bone Remodeling/drug effects , Cholecalciferol/administration & dosage , Vitamin D Deficiency/diet therapy , Adult , Alkaline Phosphatase/blood , Asian People , Biomarkers/blood , Bone Density/drug effects , Bone Density/physiology , Bone Remodeling/physiology , China , Dietary Supplements , Double-Blind Method , Female , Humans , Male , Parathyroid Hormone/blood , Peptide Fragments/blood , Procollagen/blood , Tartrate-Resistant Acid Phosphatase/blood , Vitamin D/analogs & derivatives , Vitamin D/blood , Vitamin D Deficiency/blood , Young AdultABSTRACT
To investigate the effects of 1.8 GHz radiofrequency (RF) field on bone microstructure and metabolism of femur in mice, C57BL/6 mice (male, age 4 weeks) were whole-body exposed or sham exposed to 1.8 GHz RF field. Specific absorption rates of whole body and bone were approximately 2.70 and 1.14 W/kg (6 h/day for 28 days). After exposure, microstructure and morphology of femur were observed by microcomputed tomography (micro-CT), Hematoxylin and Eosin (HE) and Masson staining. Subsequently, bone parameters were calculated directly from the reconstructed images, including structure model index, bone mineral density, trabecular bone volume/total volume, connectivity density, trabecular number, trabecular thickness, and trabecular separation. Biomarkers that reflect bone metabolism, such as serum total alkaline phosphatase (ALP), bone-specific alkaline phosphatase (BALP), and tartrate-resistant acid phosphatase 5b (TRACP-5b), were determined by biochemical assay methods. Micro-CT and histology results showed that there was no significant change in bone microstructure and the above parameters in RF group, compared with sham group. The activity of serum ALP and BALP increased 29.47% and 16.82%, respectively, in RF group, compared with sham group (P < 0.05). In addition, there were no significant differences in the activity of serum TRACP-5b between RF group and sham group. In brief, under present experimental conditions, we did not find support for an effect of 1.8 GHz RF field on bone microstructure; however, it might promote metabolic function of osteoblasts in mice. Bioelectromagnetics. 39:386-393, 2018. © 2018 Wiley Periodicals, Inc.
Subject(s)
Electromagnetic Fields , Femur/anatomy & histology , Femur/metabolism , Radio Waves , Alkaline Phosphatase/blood , Animals , Equipment Design , Femur/diagnostic imaging , Male , Mice, Inbred C57BL , Organ Size , Random Allocation , Tartrate-Resistant Acid Phosphatase/blood , X-Ray MicrotomographyABSTRACT
This study investigated whether or not vitamin D and calcium supplementation affected bone metabolism and bone mineral density (BMD) over a period of four years of denosumab therapy in patients with primary osteoporosis. Patients were divided into a denosumab monotherapy group (22 cases) or a denosumab plus vitamin D and calcium supplementation group (combination group, 21 cases). We measured serum bone alkaline phosphatase (BAP), tartrate-resistant acid phosphatase (TRACP)-5b, urinary N-terminal telopeptide of type-I collagen (NTX), and BMD of the lumbar 1-4 vertebrae (L-BMD) and bilateral hips (H-BMD) at baseline and at 12, 24, 36, and 48 months of treatment. There were no significant differences in patient background. Serum BAP, TRACP-5b, and urinary NTX were significantly and comparably inhibited in both groups from 12 to 48 months versus baseline values. L-BMD was significantly increased at every time point in both groups, while H-BMD was significantly increased at every time point in the combination group only. There were significant differences between the groups for L-BMD at 24, 36, and 48 months (P < 0.05) and for H-BMD at 12 months (P < 0.05). Compared with denosumab monotherapy, combination therapy of denosumab plus vitamin D and calcium significantly increased H-BMD at 12 months and L-BMD from 24 to 48 months. These findings indicate that continuous vitamin D and calcium supplementation is important, especially for 12 months to improve H-BMD and from 24 to 48 months to improve L-BMD.
Subject(s)
Bone Density/drug effects , Calcium, Dietary/administration & dosage , Denosumab/therapeutic use , Osteoporosis/drug therapy , Vitamin D/administration & dosage , Aged , Alkaline Phosphatase/blood , Asian People , Biomarkers/blood , Body Mass Index , Bone Resorption/blood , Bone Resorption/drug therapy , Calcium, Dietary/blood , Cohort Studies , Collagen Type I/urine , Female , Humans , Japan , Lumbar Vertebrae/drug effects , Lumbar Vertebrae/metabolism , Male , Parathyroid Hormone/blood , Peptides/urine , Phosphorus/blood , Tartrate-Resistant Acid Phosphatase/blood , Vitamin D/bloodABSTRACT
BACKGROUND: Tumor necrosis factor-alpha (TNFα), a pro-inflammatory cytokine, has been shown to play a role in the pathophysiology of rheumatoid arthritis. Silencing TNFα expression with small interfering RNA (siRNA) is a promising approach to treatment of the condition. METHODS: Towards this end, our team has developed a modified chitosan (CH) nanocarrier, deploying folic acid, diethylethylamine (DEAE) and polyethylene glycol (PEG) (folate-PEG-CH-DEAE15). The gene carrier protects siRNA against nuclease destruction, its ligands facilitate siRNA uptake via cell surface receptors, and it provides improved solubility at neutral pH with transport of its load into target cells. In the present study, nanoparticles were prepared with siRNA-TNFα, DEAE, and folic acid-CH derivative. Nanoparticle size and zeta potential were verified by dynamic light scattering. Their TNFα-knockdown effects were tested in a murine collagen antibody-induced arthritis model. TNFα expression was examined along with measurements of various cartilage and bone turnover markers by performing histology and microcomputed tomography analysis. RESULTS: We demonstrated that folate-PEG-CH-DEAE15/siRNA nanoparticles did not alter cell viability, and significantly decreased inflammation, as demonstrated by improved clinical scores and lower TNFα protein concentrations in target tissues. This siRNA nanocarrier also decreased articular cartilage destruction and bone loss. CONCLUSION: The results indicate that folate-PEG-CH-DEAE15 nanoparticles are a safe and effective platform for nonviral gene delivery of siRNA, and their potential clinical applications warrant further investigation.
Subject(s)
Arthritis, Experimental/therapy , Chitosan/analogs & derivatives , Folic Acid/chemistry , Nanoparticles/chemistry , Polyethylene Glycols/chemistry , RNA, Small Interfering/metabolism , Tumor Necrosis Factor-alpha/genetics , Alkaline Phosphatase/blood , Animals , Arthritis, Experimental/diagnostic imaging , Arthritis, Experimental/pathology , Biomarkers/blood , Bone Resorption/blood , Bone Resorption/pathology , Cartilage/pathology , Cell Survival/drug effects , Chitosan/chemical synthesis , Chitosan/chemistry , Disease Progression , Female , Gene Transfer Techniques , Inflammation Mediators/metabolism , Joints/diagnostic imaging , Joints/pathology , Mice, Inbred DBA , Osteocalcin/blood , Peptide Fragments/blood , Polyethylene Glycols/chemical synthesis , Procollagen/blood , RNA, Small Interfering/genetics , Tartrate-Resistant Acid Phosphatase/blood , Treatment Outcome , Tumor Necrosis Factor-alpha/metabolism , X-Ray MicrotomographyABSTRACT
This study aimed to explore the effects of additional weight bearing in combination with low-magnitude high-frequency vibration (LMHFV; 45 Hz, 0.3 g) on bone quality. One hundred twenty rats were randomly divided into ten groups; namely, sedentary (SED), additional weight bearing in which the rat wears a backpack whose weight is x% of the body weight (WBx; x = 5, 12, 19, 26), basic vibration (V), and additional weight bearing in combination with LMHFV in which the rat wears a backpack whose weight is x% of the body weight (Vx; x = 5, 12, 19, 26). The experiment was conducted for 12 weeks, 7 days per week, and 15 min per day. A three-point bending mechanical test, micro computed tomography, and a nanoindentation test were used. Serum samples were analyzed chemically. Failure load in V19 rats was significantly lower than that in SED rats (P < 0.05). Vx (x = 5, 12, 19, 26) rats showed poor microarchitectures. The content of tartrate-resistant acid phosphatase 5b was significantly higher in Vx (x = 5, 12, 19, 26) rats than that in SED rats (P < 0.05). V26 rats demonstrated comparatively better nanomechanical properties of materials than the other vibrational groups. Additional weight bearing in combination with LMHFV negatively affected the macromechanical properties and microarchitecture of bone. Heavy additional weight bearing, such as 26% of body weight, in combination with LMHFV was able to improve the nanomechanical properties of growing bone material compared with LMHFV. A combined mechanical stimulation was used, which may provide useful information to understand the mechanism of this mechanical stimulation on bone.
Subject(s)
Bone Development , Bone and Bones/physiology , Vibration , Alkaline Phosphatase/blood , Animals , Biomechanical Phenomena , Body Weight , Bone Density , Bone and Bones/anatomy & histology , Bone and Bones/diagnostic imaging , Calcium/blood , Elastic Modulus , Female , Femur/anatomy & histology , Femur/diagnostic imaging , Femur/physiology , Hardness , Imaging, Three-Dimensional , Muscles/anatomy & histology , Muscles/physiology , Organ Size , Phosphorus/blood , Rats, Sprague-Dawley , Rats, Wistar , Tartrate-Resistant Acid Phosphatase/blood , Weight-Bearing , X-Ray MicrotomographyABSTRACT
Sustained elevation of parathyroid hormone (PTH) is catabolic to cortical bone, as evidenced by deterioration in bone structure (cortical porosity), and is a major factor for increased fracture risk in chronic kidney disease (CKD). Etelcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces PTH levels in subtotal nephrectomized (Nx) rats and in hemodialysis patients with secondary hyperparathyroidism (SHPT) in clinical studies; however, effects of etelcalcetide on bone have not been determined. In a rat model of established SHPT with renal osteodystrophy, etelcalcetide or vehicle was administered by subcutaneous (s.c.) injection to subtotal Nx rats with elevated PTH (>750pg/mL) once per day for 6weeks. Sham-operated rats receiving vehicle (s.c.) served as non-SHPT controls. Prior to treatment, significant increases in serum creatinine (2-fold), blood urea nitrogen (BUN, 3-fold), PTH (5-fold), fibroblast growth factor-23 (FGF23; 13-fold) and osteocalcin (12-fold) were observed in SHPT rats compared to non-SHPT controls. Elevations in serum creatinine and BUN were unaffected by treatment with vehicle or etelcalcetide. In contrast, etelcalcetide significantly decreased PTH, FGF23 and osteocalcin, whereas vehicle treatment did not. Cortical bone porosity increased and bone strength decreased in vehicle-treated SHPT rats compared to non-SHPT controls. Cortical bone structure improved and energy to failure was significantly greater in SHPT rats treated with etelcalcetide compared to vehicle. Mineralization lag time and marrow fibrosis were significantly reduced by etelcalcetide. In conclusion, etelcalcetide reduced bone turnover, attenuated mineralization defect and marrow fibrosis, and preserved cortical bone structure and bone strength by lowering PTH in subtotal Nx rats with established SHPT.
Subject(s)
Cortical Bone/physiopathology , Hyperparathyroidism, Secondary/drug therapy , Hyperparathyroidism, Secondary/physiopathology , Nephrectomy , Peptides/therapeutic use , Receptors, Calcium-Sensing/agonists , Animals , Biomechanical Phenomena/drug effects , Blood Urea Nitrogen , Calcium/blood , Cortical Bone/drug effects , Creatinine/blood , Fibroblast Growth Factor-23 , Fibroblast Growth Factors/blood , Hyperparathyroidism, Secondary/blood , Hyperplasia , Kidney Function Tests , Male , Osteocalcin/blood , Parathyroid Glands/pathology , Parathyroid Hormone/blood , Peptides/pharmacology , Phosphorus/blood , Rats, Sprague-Dawley , Tartrate-Resistant Acid Phosphatase/bloodABSTRACT
Ibandronate (IBN) and pulsed electromagnetic field (PEMF) have each shown positive effects for treating osteoporosis, but no study has evaluated the relative effects of these treatments combined. This study investigated the effects of IBN + PEMF on bone turnover, mineral density, microarchitecture, and biomechanical properties in an ovariectomized (OVX) rat model of osteoporosis. Fifty 3-month-old rats were randomly apportioned to receive a sham-operation (n = 10), or ovariectomy (n = 40). The latter group was equally divided as the model (OVX control) or to receive IBN, PEMF, or IBN + PEMF. Beginning the day after surgery, the IBN and IBN + PEMF groups received weekly subcutaneous IBN; the PEMF and IBN + PEMF groups were given daily PEMF during the same 12 weeks. After 12 weeks of treatments, biochemical parameters, bone mineral density (BMD), microarchitecture parameters, biomechanical properties, and some metabolic modulators that are involved in bone resorption were compared. The L5 lumbar vertebral body BMDs of the IBN, PEMF, and IBN + PEMF groups were 121.6%, 119.5%, and 139.6%; maximum loads were 111.4%, 112.7%, and 121.9%; and energy to failure was 130.8%, 129.2%, and 154.9% of the OVX model, respectively. The IBN + PEMF group had significantly lower levels of serum tartrate-resistant acid phosphatase 5b, and greater improvement in BMD, bone microarchitecture, and strength of the lumbar spine compared with monotherapy groups. Results showed that IBN + PEMF had a more favorable effect on the lumbar spine in this osteoporosis model than did either monotherapy. Bioelectromagnetics. 38:31-40, 2017. © 2016 Wiley Periodicals, Inc.
Subject(s)
Diphosphonates/pharmacology , Electromagnetic Fields , Magnetic Field Therapy , Osteoporosis/etiology , Osteoporosis/therapy , Ovariectomy/adverse effects , Animals , Biomechanical Phenomena , Bone Density/drug effects , Bone Density/radiation effects , Combined Modality Therapy , Diphosphonates/therapeutic use , Female , Femur/drug effects , Femur/physiopathology , Femur/radiation effects , Gene Expression Regulation/drug effects , Gene Expression Regulation/radiation effects , Ibandronic Acid , Osteoporosis/metabolism , Osteoporosis/physiopathology , Osteoprotegerin/genetics , RANK Ligand/genetics , RNA, Messenger/genetics , RNA, Messenger/metabolism , Rats , Spine/drug effects , Spine/physiopathology , Spine/radiation effects , Tartrate-Resistant Acid Phosphatase/blood , X-Ray MicrotomographyABSTRACT
UNLABELLED: Macrophages play an important role during the development of steroid-induced osteonecrosis. Interleukin (IL)-4 administration helped reduce the infiltration of M1 phenotypic macrophages and maintain the activation of M2 phenotypic macrophages, resulting in restriction of inflammation and decrease in osteocyte apoptosis. The results indicated the therapeutic potential of IL-4 in prevention of steroid-induced osteonecrosis. INTRODUCTION: Steroid-induced osteonecrosis (ON) is a debilitating disease characterized by the activation and infiltration of macrophages into the necrotic site. This study aimed to investigate the effects of IL-4 administration on macrophage polarization and the involved signaling pathways. METHODS: Fifty-six BALB/c mice were randomly divided into two groups, group M (model group) and group MI (treatment group), each containing 28 mice. ON model was induced by the injection of methylprednisolone (MPS). The mice in group MI received intra-abdominal injections of 2 µg/100 g/day of rIL-4 for five consecutive days, following the administration of MPS. Osteonecrosis was verified by histopathological staining. The expression of tumor necrosis factor-alpha (TNF-α) was analyzed by ELISA and immunohistochemistry. The infiltration of M1/M2 macrophages was examined by the expression of specific makers of F4/80, CD11c, and CD206 protein. Cell apoptosis was detected by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay, and the apoptotic signal molecules such as STAT1 and caspase-3 were examined. RESULTS: Histopathological observations indicated that IL-4 administration reduced the incidence of ON and the accumulation of osteoclasts. IL-4 administration inhibited the expression of TNF-α and reduced the infiltration of M1 phenotypic macrophages and maintained relatively high level of M2 phenotypic macrophages. Additionally, TUNEL assay suggested that IL-4 intervention could reduce the number of apoptotic cells in the necrotic zone. The anti-apoptotic mechanisms were related to STAT1 phosphorylation and the activation of caspase-3. CONCLUSIONS: Il-4 administration could alleviate steroid associated ON in mice by inhibiting the inflammatory response, the infiltration of M1 phenotypic macrophages, and suppressing TNF-a-induced osteocytic apoptosis by inhibiting the STAT1-caspase-3 signal pathway.